icon
icon
icon
icon
Upgrade
icon

Most monkeypox stocks rose, with Virax Biolabs (VRAX.US) rising nearly 190%.

AInvestMonday, Aug 19, 2024 10:40 am ET
1min read

As of the time of writing, most of the monkeypox stocks rose on Monday. Virax Biolabs (VRAX.US) rose nearly 190%, Applied DNA Sciences (APDN.US) rose nearly 130%, Tonix Pharmaceuticals (TNXP.US) rose nearly 50%, Geovax Labs (GOVX.US) rose more than 29%, Co-Diagnostic (CDOX.US) rose nearly 18%, Chimerix (CMRX.US) rose 0.02%; Siga Technologies (SIGA.US) fell more than 5.8%, Emergent Biosolutions (EBS.US) fell more than 1.2%. On Monday, the Philippine Department of Health announced the country's first case of the monkeypox virus since December last year, after the latest cases were reported in Sweden and Pakistan.

The number of suspected or confirmed monkeypox cases reported in Africa this year has surpassed the total number of cases reported in the whole of last year. The WHO Director-General declared the monkeypox outbreak a public health emergency of international concern on August 14, and the monkeypox stocks have been rising since then.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.